Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop a highly accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
Natera San Carlos

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

May 3, 2021
Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 Annual ASCO Meeting
ASCO presentations come on the heels of new Signatera™ data in ovarian cancer presented at AACR AUSTIN, Texas , May 3, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present 4 posters at the 2021 American Society of
April 29, 2021
Natera Announces First Quarter 2021 Earnings Conference Call
AUSTIN, Texas , April 29, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2021, after the market close on May 6, 2021.
April 22, 2021
Prospera™ Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple Organs
Medicare issues new coverage guidance for dd-cfDNA testing, enabling coverage beyond kidney transplants AUSTIN, Texas , April 22, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and a global leader in cell-free DNA testing, receives pathway to future coverage for the Prospera
April 7, 2021
Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS
AUSTIN, Texas , April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has implemented the first wave of Panorama AI innovations following the breakthrough results shared earlier from the SMART study.
March 31, 2021
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
AUSTIN, Texas , March 31, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs , a US multi-region lab services provider with labs in Colorado, Texas and Arizona , announced a strategic partnership in

Upcoming Events

Past events